A deep dive into BTK degraders for the treatment of CLL

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, takes a deep dive into the use of BTK degraders for the treatment of chronic lymphocytic leukemia (CLL). He discusses the mechanism of action, agents in development, associated toxicities, and how these agents may change the CLL treatment landscape. This interview was recorded via an online conference call with The Video Journal of Hematology and Hematological Oncology (VJHemOnc).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next